Identifying 18F-FDG PET-metabolic radiomic signature for lung adenocarcinoma prognosis via the leveraging of prognostic transcriptomic module

Identifying 18F-FDG PET-metabolic radiomic signature for lung adenocarcinoma prognosis via the leveraging of prognostic transcriptomic module

BackgroundImaging with 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET), which identifies molecular and metabolic abnormalities within tumor cells, could support prognostic assessment of lung adenocarcinoma (LUAD). We aimed to develop a radiomic signature with the aid of a transcrip...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Quantitative imaging in medicine and surgery 2022-03, Vol.12 (3), p.1893-1908
Hauptverfasser: Li, Jin, Liu, Yixin, Dong, Wenlei, Zhou, Yang, Wu, Jingquan, Luan, Kuan, Qi, Lishuang
Format: Artikel
Sprache:eng
Schlagworte:
Original
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1908
container_issue 3
container_start_page 1893
container_title Quantitative imaging in medicine and surgery
container_volume 12
creator Li, Jin
Liu, Yixin
Dong, Wenlei
Zhou, Yang
Wu, Jingquan
Luan, Kuan
Qi, Lishuang
description BackgroundImaging with 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET), which identifies molecular and metabolic abnormalities within tumor cells, could support prognostic assessment of lung adenocarcinoma (LUAD). We aimed to develop a radiomic signature with the aid of a transcriptomic module for individualized clinical prognostic assessment of LUAD patients. MethodsUsing a gene expression profile consisting of 334 stage I-IIIA LUAD patients, prognostic-related gene coexpression modules were constructed via a weighted correlation network analysis algorithm. The robustness and prognostic performance of the coexpression modules were then tested across 2 gene expression datasets totaling 331 patients. Finally, using a discovery dataset with matched transcriptomic and 18F-FDG PET radiomic data of 15 patients and multiple linear regression analysis, we developed a PET-metabolic radiomic signature that had optimal correlation with the expression of a robust prognostic module. ResultsWe selected a superior coexpression module for LUAD prognosis in which the genes were significantly enriched in important biological processes associated with tumors (e.g., cell cycle, DNA replication and p53 signaling pathway). The prognostic performance of the module for overall survival (OS) and recurrence-free survival (RFS) was validated in 2 independent gene expression datasets (log-rank P
doi_str_mv 10.21037/qims-21-706
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8899934</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2638944766</sourcerecordid><originalsourceid>FETCH-LOGICAL-c361t-b3749430c0d53e40d47937c696fede4054893d9ed44d8422c25aebc08e5b91613</originalsourceid><addsrcrecordid>eNpVkctq3TAQhkVpaUKaXR9AyyzqVjdL1iZQ0pw0cCBdpGshS2NHxbZOJPlAHiLvHJ1cCpnN_GJmvmH0I_SVku-MEq5-3Ic5N4w2isgP6JgxxhvBifz4pplmR-g053-khuqoouQzOuIt6wST6hg9XntYShgewjJi2m2aza8r_Ofytpmh2D5OweFkfYhzFTmMiy1rAjzEhKe1Ttg6HZ1NLixxtniX4rjEHDLeB4vLHeAJ9pDseKDH4a1eKqwku2SXwq48s-fo1wm-oE-DnTKcvuYT9HdzeXvxu9neXF1f_Nw2jktamp4roeuZjviWgyBeKM2Vk1oO4Ou7FZ3mXoMXwtc7mWOthd6RDtpeU0n5CTp_4e7Wfgbv6hckO5ldCrNNDybaYN5XlnBnxrg3Xae15qICzl4BKd6vkIuZQ3YwTXaBuGbDJO-0EErK2vrtpdWlmHOC4f8aSsyzieZgYpWmmsifABvokfk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2638944766</pqid></control><display><type>article</type><title>Identifying 18F-FDG PET-metabolic radiomic signature for lung adenocarcinoma prognosis via the leveraging of prognostic transcriptomic module</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Li, Jin ; Liu, Yixin ; Dong, Wenlei ; Zhou, Yang ; Wu, Jingquan ; Luan, Kuan ; Qi, Lishuang</creator><creatorcontrib>Li, Jin ; Liu, Yixin ; Dong, Wenlei ; Zhou, Yang ; Wu, Jingquan ; Luan, Kuan ; Qi, Lishuang</creatorcontrib><description>BackgroundImaging with 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET), which identifies molecular and metabolic abnormalities within tumor cells, could support prognostic assessment of lung adenocarcinoma (LUAD). We aimed to develop a radiomic signature with the aid of a transcriptomic module for individualized clinical prognostic assessment of LUAD patients. MethodsUsing a gene expression profile consisting of 334 stage I-IIIA LUAD patients, prognostic-related gene coexpression modules were constructed via a weighted correlation network analysis algorithm. The robustness and prognostic performance of the coexpression modules were then tested across 2 gene expression datasets totaling 331 patients. Finally, using a discovery dataset with matched transcriptomic and 18F-FDG PET radiomic data of 15 patients and multiple linear regression analysis, we developed a PET-metabolic radiomic signature that had optimal correlation with the expression of a robust prognostic module. ResultsWe selected a superior coexpression module for LUAD prognosis in which the genes were significantly enriched in important biological processes associated with tumors (e.g., cell cycle, DNA replication and p53 signaling pathway). The prognostic performance of the module for overall survival (OS) and recurrence-free survival (RFS) was validated in 2 independent gene expression datasets (log-rank P&lt;0.05). Through the leveraging of this prognostic coexpression module, a radiomic signature consisting of 3 PET features associated with metabolic processes was developed in the discovery dataset. The radiomic signature was significantly associated with patients' OS and RFS in an independent PET dataset consisting of 72 LUAD patients (OS: log-rank P=0.0006; RFS: log-rank P=0.0013). Multivariate Cox analysis demonstrated that the radiomic signature was an independent prognostic factor for OS and RFS. Furthermore, the novel proposed radiomic nomograms for OS and RFS had significantly better performance (concordance indices) than did the clinicopathological nomograms. ConclusionsThe radiomic signature, which reflects biological processes in tumors (e.g., cell cycle and p53 signaling pathway), could noninvasively identify LUAD patients with poor prognosis who should receive postoperative adjuvant treatment. The signature is suitable for clinical application and could be robustly applied at an individual level across multicenter cohorts.</description><identifier>ISSN: 2223-4292</identifier><identifier>EISSN: 2223-4306</identifier><identifier>DOI: 10.21037/qims-21-706</identifier><identifier>PMID: 35284267</identifier><language>eng</language><publisher>AME Publishing Company</publisher><subject>Original</subject><ispartof>Quantitative imaging in medicine and surgery, 2022-03, Vol.12 (3), p.1893-1908</ispartof><rights>2022 Quantitative Imaging in Medicine and Surgery. All rights reserved. 2022 Quantitative Imaging in Medicine and Surgery.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c361t-b3749430c0d53e40d47937c696fede4054893d9ed44d8422c25aebc08e5b91613</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899934/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899934/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Li, Jin</creatorcontrib><creatorcontrib>Liu, Yixin</creatorcontrib><creatorcontrib>Dong, Wenlei</creatorcontrib><creatorcontrib>Zhou, Yang</creatorcontrib><creatorcontrib>Wu, Jingquan</creatorcontrib><creatorcontrib>Luan, Kuan</creatorcontrib><creatorcontrib>Qi, Lishuang</creatorcontrib><title>Identifying 18F-FDG PET-metabolic radiomic signature for lung adenocarcinoma prognosis via the leveraging of prognostic transcriptomic module</title><title>Quantitative imaging in medicine and surgery</title><description>BackgroundImaging with 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET), which identifies molecular and metabolic abnormalities within tumor cells, could support prognostic assessment of lung adenocarcinoma (LUAD). We aimed to develop a radiomic signature with the aid of a transcriptomic module for individualized clinical prognostic assessment of LUAD patients. MethodsUsing a gene expression profile consisting of 334 stage I-IIIA LUAD patients, prognostic-related gene coexpression modules were constructed via a weighted correlation network analysis algorithm. The robustness and prognostic performance of the coexpression modules were then tested across 2 gene expression datasets totaling 331 patients. Finally, using a discovery dataset with matched transcriptomic and 18F-FDG PET radiomic data of 15 patients and multiple linear regression analysis, we developed a PET-metabolic radiomic signature that had optimal correlation with the expression of a robust prognostic module. ResultsWe selected a superior coexpression module for LUAD prognosis in which the genes were significantly enriched in important biological processes associated with tumors (e.g., cell cycle, DNA replication and p53 signaling pathway). The prognostic performance of the module for overall survival (OS) and recurrence-free survival (RFS) was validated in 2 independent gene expression datasets (log-rank P&lt;0.05). Through the leveraging of this prognostic coexpression module, a radiomic signature consisting of 3 PET features associated with metabolic processes was developed in the discovery dataset. The radiomic signature was significantly associated with patients' OS and RFS in an independent PET dataset consisting of 72 LUAD patients (OS: log-rank P=0.0006; RFS: log-rank P=0.0013). Multivariate Cox analysis demonstrated that the radiomic signature was an independent prognostic factor for OS and RFS. Furthermore, the novel proposed radiomic nomograms for OS and RFS had significantly better performance (concordance indices) than did the clinicopathological nomograms. ConclusionsThe radiomic signature, which reflects biological processes in tumors (e.g., cell cycle and p53 signaling pathway), could noninvasively identify LUAD patients with poor prognosis who should receive postoperative adjuvant treatment. The signature is suitable for clinical application and could be robustly applied at an individual level across multicenter cohorts.</description><subject>Original</subject><issn>2223-4292</issn><issn>2223-4306</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVkctq3TAQhkVpaUKaXR9AyyzqVjdL1iZQ0pw0cCBdpGshS2NHxbZOJPlAHiLvHJ1cCpnN_GJmvmH0I_SVku-MEq5-3Ic5N4w2isgP6JgxxhvBifz4pplmR-g053-khuqoouQzOuIt6wST6hg9XntYShgewjJi2m2aza8r_Ofytpmh2D5OweFkfYhzFTmMiy1rAjzEhKe1Ttg6HZ1NLixxtniX4rjEHDLeB4vLHeAJ9pDseKDH4a1eKqwku2SXwq48s-fo1wm-oE-DnTKcvuYT9HdzeXvxu9neXF1f_Nw2jktamp4roeuZjviWgyBeKM2Vk1oO4Ou7FZ3mXoMXwtc7mWOthd6RDtpeU0n5CTp_4e7Wfgbv6hckO5ldCrNNDybaYN5XlnBnxrg3Xae15qICzl4BKd6vkIuZQ3YwTXaBuGbDJO-0EErK2vrtpdWlmHOC4f8aSsyzieZgYpWmmsifABvokfk</recordid><startdate>202203</startdate><enddate>202203</enddate><creator>Li, Jin</creator><creator>Liu, Yixin</creator><creator>Dong, Wenlei</creator><creator>Zhou, Yang</creator><creator>Wu, Jingquan</creator><creator>Luan, Kuan</creator><creator>Qi, Lishuang</creator><general>AME Publishing Company</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202203</creationdate><title>Identifying 18F-FDG PET-metabolic radiomic signature for lung adenocarcinoma prognosis via the leveraging of prognostic transcriptomic module</title><author>Li, Jin ; Liu, Yixin ; Dong, Wenlei ; Zhou, Yang ; Wu, Jingquan ; Luan, Kuan ; Qi, Lishuang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c361t-b3749430c0d53e40d47937c696fede4054893d9ed44d8422c25aebc08e5b91613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Li, Jin</creatorcontrib><creatorcontrib>Liu, Yixin</creatorcontrib><creatorcontrib>Dong, Wenlei</creatorcontrib><creatorcontrib>Zhou, Yang</creatorcontrib><creatorcontrib>Wu, Jingquan</creatorcontrib><creatorcontrib>Luan, Kuan</creatorcontrib><creatorcontrib>Qi, Lishuang</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Quantitative imaging in medicine and surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Jin</au><au>Liu, Yixin</au><au>Dong, Wenlei</au><au>Zhou, Yang</au><au>Wu, Jingquan</au><au>Luan, Kuan</au><au>Qi, Lishuang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identifying 18F-FDG PET-metabolic radiomic signature for lung adenocarcinoma prognosis via the leveraging of prognostic transcriptomic module</atitle><jtitle>Quantitative imaging in medicine and surgery</jtitle><date>2022-03</date><risdate>2022</risdate><volume>12</volume><issue>3</issue><spage>1893</spage><epage>1908</epage><pages>1893-1908</pages><issn>2223-4292</issn><eissn>2223-4306</eissn><abstract>BackgroundImaging with 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET), which identifies molecular and metabolic abnormalities within tumor cells, could support prognostic assessment of lung adenocarcinoma (LUAD). We aimed to develop a radiomic signature with the aid of a transcriptomic module for individualized clinical prognostic assessment of LUAD patients. MethodsUsing a gene expression profile consisting of 334 stage I-IIIA LUAD patients, prognostic-related gene coexpression modules were constructed via a weighted correlation network analysis algorithm. The robustness and prognostic performance of the coexpression modules were then tested across 2 gene expression datasets totaling 331 patients. Finally, using a discovery dataset with matched transcriptomic and 18F-FDG PET radiomic data of 15 patients and multiple linear regression analysis, we developed a PET-metabolic radiomic signature that had optimal correlation with the expression of a robust prognostic module. ResultsWe selected a superior coexpression module for LUAD prognosis in which the genes were significantly enriched in important biological processes associated with tumors (e.g., cell cycle, DNA replication and p53 signaling pathway). The prognostic performance of the module for overall survival (OS) and recurrence-free survival (RFS) was validated in 2 independent gene expression datasets (log-rank P&lt;0.05). Through the leveraging of this prognostic coexpression module, a radiomic signature consisting of 3 PET features associated with metabolic processes was developed in the discovery dataset. The radiomic signature was significantly associated with patients' OS and RFS in an independent PET dataset consisting of 72 LUAD patients (OS: log-rank P=0.0006; RFS: log-rank P=0.0013). Multivariate Cox analysis demonstrated that the radiomic signature was an independent prognostic factor for OS and RFS. Furthermore, the novel proposed radiomic nomograms for OS and RFS had significantly better performance (concordance indices) than did the clinicopathological nomograms. ConclusionsThe radiomic signature, which reflects biological processes in tumors (e.g., cell cycle and p53 signaling pathway), could noninvasively identify LUAD patients with poor prognosis who should receive postoperative adjuvant treatment. The signature is suitable for clinical application and could be robustly applied at an individual level across multicenter cohorts.</abstract><pub>AME Publishing Company</pub><pmid>35284267</pmid><doi>10.21037/qims-21-706</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2223-4292
ispartof Quantitative imaging in medicine and surgery, 2022-03, Vol.12 (3), p.1893-1908
issn 2223-4292
2223-4306
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8899934
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Original
title Identifying 18F-FDG PET-metabolic radiomic signature for lung adenocarcinoma prognosis via the leveraging of prognostic transcriptomic module
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T14%3A36%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identifying%2018F-FDG%20PET-metabolic%20radiomic%20signature%20for%20lung%20adenocarcinoma%20prognosis%20via%20the%20leveraging%20of%20prognostic%20transcriptomic%20module&rft.jtitle=Quantitative%20imaging%20in%20medicine%20and%20surgery&rft.au=Li,%20Jin&rft.date=2022-03&rft.volume=12&rft.issue=3&rft.spage=1893&rft.epage=1908&rft.pages=1893-1908&rft.issn=2223-4292&rft.eissn=2223-4306&rft_id=info:doi/10.21037/qims-21-706&rft_dat=%3Cproquest_pubme%3E2638944766%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2638944766&rft_id=info:pmid/35284267&rfr_iscdi=true